<DOC>
	<DOCNO>NCT02762383</DOCNO>
	<brief_summary>This uncontrolled , open-label , Phase III trial peginterferon alfa-2a ( Pegasys ) participant coinfected human immunodeficiency virus ( HIV ) hepatitis C virus ( HCV ) . Participants HIV/HCV show negative reduce HCV ribonucleic acid ( RNA ) least 12 week treatment peginterferon alfa-2a plus ribavirin receive low dose peginterferon alfa-2a 18 month . The primary objective evaluate safety tolerability . Secondary objective evaluate histological , virological , biochemical effect .</brief_summary>
	<brief_title>Pegasys Long-Term Anti-Fibrotic Effect Co-Infection Trial ( PERFECT )</brief_title>
	<detailed_description />
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Serologic evidence chronic hepatitis C infection antiHCV antibody test Received peginterferon alfa2a least 12 week either reach 2log drop HCV RNA 12 week treatment , reach undetectable HCV RNA 24 week treatment , reach undetectable HCV RNA detectable end 48 week treatment Detectable serum HCV RNA Screening Serologic evidence HIV infection HIV RNA detection CD4 cell count great equal ( &gt; /= ) 100 cells/mcL therapy peginterferon alfa2a plus ribavirin least 12 week Stable HIV status , antiretroviral therapy , stable regimen least 6 week prior Baseline Compensated liver disease No evidence hepatocellular carcinoma Pregnant breastfeeding Antineoplastic immunomodulatory treatment within 6 month prior first dose Any investigational drug within 6 week prior first dose Positive hepatitis A immunoglobulin M antibody Severe neutropenia thrombocytopenia Screening still therapy peginterferon alfa2a plus ribavirin Severe psychiatric neurologic comorbidity History significant medical condition , immune disorder disease major organ system Uncontrolled thyroid disease Severe retinopathy Evidence drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>